Exozymes Inc (EXOZ)

$EXOZ 5 million preferred share offering. Poision pill? https://investorshub.advfn.com/stock-market/NASDAQ/exozymes-EXOZ/stock-news/97634377/form-s-3-registration-statement-under-securities

$EXOZ “We need the last and most important thing: commercial scale” eXoZymes is planning on scaling their technology in Q3 (July-September) this year! One of the final major derisking events for their platform

$EXOZ A must watch for those interested in eXoZymes! Three of the company’s heavy hitters sit down and discuss the events of 2025 as well as the MASSIVE opportunities in 2026 and beyond https://exozymes.twentythree.com/secret/120191657/81412a44701bd80b4e8b55c7eb00d485?autoPlay=1&some&utm_campaign=209775304-Heltzen%27s%20Video%20Highlights&utm_source=twitter&utm_medium=social

$EXOZ RSI: 7.83, MACD: -0.9061 Vol: 1.59, MA20: 13.25, MA50: 13.92 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$EXOZ RSI: 32.61, MACD: -0.7854 Vol: 1.52, MA20: 13.69, MA50: 13.98 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

In a recent International Business Times article, eXoZymes (Nasdaq: $EXOZ ) addressed one of biotech’s persistent frustrations: why promising molecules discovered in the lab so rarely make it to commercial scale. eXoZymes Inc. is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. The article examines the track record of cell-based synthetic biology approaches, which have often underdelivered on their promise. Living cells, it turns out, resist being repurposed as factories. They produce only what benefits them, in the amounts they need, and scaling production from lab bench to industrial bioreactor has proven stubbornly difficult. As described in the article, eXoZymes takes a different approach: using AI to engineer enzymes that work outside of cells entirely, in controlled bioreactors where temperature, pH, and other variables can be optimized for maximum yield. CEO Michael Heltzen framed the challenge this way: “Cells weren’t built to manufacture what we need, and they fight us every step of the way as they only want to make chemicals they themselves benefit from and only at the amount they need it. Using AI-engineered eXoZymes, we flip the model, as there are no living cells in our biosolutions.” According to the article, the company reports feedstock-to-product conversion efficiency exceeding 90 percent. Read the complete article: https://www.ibtimes.com/ai-meets-enzymes-exozymes-enables-high-yield-production-compounds-previously-impossible-make-3792509 eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, Ph.D., VP of Business Development; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

$EXOZ This is a pump and dump. Employees should abandon stock into year end

$EXOZ A reminder to all the new followers that we have set up a eXoZymes discord group Link in the posts comments

$DNA $EXOZ yup, everyone should gather around and listen to your wisdom so in 9 months we all can end up in the -51% in the red. Should change your nick to horse sh#t and your opinion as horse sh$T report.

$DNA Detailing why Cell-based Biomanuafcturing will never economically scale... The next generation of biomanufacturing is already underway, with $EXOZ recently reporting a near-theoretical conversion yield of 99% in its pilot-plant scale up activites... https://www.ibtimes.com/ai-meets-enzymes-exozymes-enables-high-yield-production-compounds-previously-impossible-make-3792509

https://www.ibtimes.com/ai-meets-enzymes-exozymes-enables-high-yield-production-compounds-previously-impossible-make-3792509 $EXOZ

$BEAT $EXOZ if you are looking for another rocket ship - this one is brought to you by the same VC company - a very smart group with a great track record of finding and launching Big Idea companies

eXoZymes (Nasdaq: $EXOZ ) announced the achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process, demonstrating over 99% conversion from feedstock to product using its proprietary exozyme-based, cell-free biomanufacturing platform. eXoZymes Inc. is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. The announcement validates the scalability of eXoZymes’ cell-free enzyme technology, proving that complex biocatalytic reactions can maintain exceptional efficiency at industrial volumes. The scaled production was executed under partner-operated conditions by Cayman Chemical using standardized protocols, demonstrating that the exozyme technology can be successfully transferred to and operated by manufacturing partners. This milestone also demonstrates that enzyme-driven systems freed from cellular constraints can overcome fundamental limitations that have historically hampered commercial biomanufacturing. Several important competitive advantages were demonstrated by the announced breakthrough: • 100× Scale-Up Success: The reaction scaled from laboratory to industrial volumes while maintaining performance, proving linear scalability of the exozyme platform • Near-Perfect Efficiency: Over 99% conversion of feedstock to product achieved at scale, matching or exceeding small-scale conversion levels • Partner Validation: Production executed by Cayman Chemical, confirming process transferability • Cell-Free Advantage: Removing cellular constraints enables reliable, scalable production of molecules previously limited by traditional biomanufacturing Michael Heltzen, CEO of eXoZymes, commented, “Scaling a complex biocatalytic reaction by 100× while sustaining high feedstock conversion strengthens our belief that exozymes will form the foundation of the next generation of biomanufacturing. We’re very enthusiastic about this progress and see it as an important inflection point in demonstrating that cell-free, enzyme-driven systems can be engineered to operate reliably at scale. This truly opens the door to producing molecules that have historically been constrained by traditional manufacturing approaches.” Dr. Tyler Korman, CSO of eXoZymes, added further, “Achieving over 99% conversion at scale is a significant validation of our exozyme biosolution - both from a scientific as well as a commercial point of view.” Read the complete announcement: https://exozymes.com/blog/100x-scale-up eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, Ph.D., VP of Business Development; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

$EXOZ A significant milestone in scaling their NCT production 100x… achieving a 99% yield compared to prior 4-gram production of 96% NCT is launching in late 2026, targeting a $200B+ market with no other company currently able to produce NCT economically https://exozymes.com/blog/100x-scale-up?utm_campaign=196039362-202512%20100x%20scale-up&utm_content=384517845&utm_medium=social&utm_source=twitter&hss_channel=tw-1890406768372502528

$EXOZ $BEAT

$EXOZ I was having a further think over eXoZymes' R&D process and after some research, I think this is what the company may do... PART ONE 1. Define the target compound's chemical formula and structure 2. Using Retrobiosynthesis, they then work backwards from the target to the starting feedstock (sugar) to map possible: - a: Enzyme cascades using both external enzyme databases and their own internal database and AI computational design tools. With time, eXoZymes' internal database will expand with lots of Exozyme data, so this stage will get faster - b: The supportive frameworks and systems, including the enzymes required to recycle cofactors 3. They then use high-performance Computational Protein Design to assess the possible production Systems' performance data (maximum yield etc) as well as broadly model the economic feasibility of production PART TWO 4: Grow the required enzymes and Exozymes in cells and harvest them continued in comments...

$EXOZ Added a few more here today. $1 Bn cap in 2026?

$EXOZ NCT as a supportive supplement to GLP-1s In a pivotal mouse study, NCT given alongside a high-fat diet led to 35-40% less weight gain compared to mice just on a high-fat diet. On its own, NCT doesn't cause rapid weight loss. In another study, obese mice given NCT for 2 weeks saw no drop in body weight however, it did reverse their fatty livers. This suggests NCT may help people maintain normal eating patterns without putting on as much weight. For those already obese, GLP-1s could be used for rapid initial weight loss and then NCT could be taken afterwards for maintenance and weight gain prevention. NCT keeps metabolism rates high, effectively fighting the body's natural tendency to slow down metabolism and regain weight. It also helps reverse obesity-related mitochondrial and liver damage. Importantly, it promotes lipophagy, where liver cells break down their own stored fat. A clearer, healthier liver directs incoming calories toward energy production instead of fat storage.

$EXOZ Great to see new investors following the company! Just a reminder that we've set up an eXoZymes Investor Discord